Janssen Scientific Affairs, LLC

Quick facts

Marketed products

• aspirin (ASA) · Cardiovascular; Pain management; Immunology
  Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.
• Darunavir/Cobicistat (FDC) · Infectious Disease
  Darunavir is a protease inhibitor that blocks HIV protease to prevent viral replication, while cobicistat is a boosting agent that inhibits CYP3A4 to increase darunavir levels.
• haloperidole · Other
• INI Based Regimen
• Nucynta ER
• TAF/FTC FDC · Infectious Disease / Virology
  TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.

Phase 3 pipeline

• Adalimumab (40 mg) · Immunology
  Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
• Placebo for Adalimumab
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Placebo for Ustekinumab
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Ustekinumab (90 mg) · Immunology
  Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.

Phase 2 pipeline

• Cilta-cel OOS Therapy · Oncology
  Chimeric antigen receptor T-cell therapy
• Other Antipsychotics - New Starts
• Other Biologic Therapies

Phase 1 pipeline

• Kcentra, a 4-factor PCC
• Tramadol HCl, 50 mg

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Janssen Scientific Affairs, LLC portfolio CI brief
• Janssen Scientific Affairs, LLC pipeline updates RSS